Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kexia Chai"'
Autor:
Hua Ye, Shengyun Liu, Jian Xu, Kexia Chai, Dongyi He, Yongfei Fang, Qibing Xie, Huaxiang Liu, Ying Liu, Bingzhu Hua, Jiankang Hu, Zhiyi Zhang, Mingxuan Zhou, Dongbao Zhao, Yan Li, Zhenyu Jiang, Meimei Wang, Jingyang Li, Zhuoli Zhang, Xiaomei Li, Yang Li, Erwei Sun, Liqi Bi, Wei Wei, Ning Tie, Lan He, Xiangyang Huang, Yan Zhang, Qingchun Huang, Xiaofei Wang, Xiangyuan Liu, Jing Li, Yin Su
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 3, Pp 757-773 (2023)
Abstract Objectives The aim of this work is to verify the non-inferior efficacy and safety of CMAB008 compared with innovator infliximab in rheumatoid arthritis patients combined with methotrexate. Methods We conducted a randomized, double-blinded, p
Externí odkaz:
https://doaj.org/article/36bf076d47534c6eaf652f8daa9e5540
Autor:
Ju Liu, Fuai Lu, Niansheng Yang, Lie Dai, Yingxue Cathy Liu, Ning Tie, Lin Liu, Xiumei Liu, Kexia Chai, Xiaowei Gong, H. Sun, Y Wang, Zhenyu Jiang, Lingyun Sun, Guixiu Shi, Xiaomei Li, Jian Wu, Cheng Zhao, Zhanyun Da, Ling Wang, Hua Wei, Zhenchun Zhang, Zhanguo Li, Yanying Liu, Li Luo, Jinying Lin, Linjie Chen, Qian Guo, Lijun Wu, Hui Song, Shengyun Liu
Publikováno v:
Rheumatology and Therapy. 9:175-189
This phase III trial (NCT04178850) evaluated the efficacy, safety, and immunogenicity of GB242, an infliximab biosimilar, vs. infliximab (Remicade®) reference product in patients with moderate-to-severe active rheumatoid arthritis (RA) combination w
Publikováno v:
Journal of Clinical Laboratory Analysis. 36
Publikováno v:
Journal of clinical laboratory analysis. 36(9)
The objective of this study is to investigate the expression levels of ThA total of 20 pSS patients and 20 healthy people, matched with age and gender, were selected as the experimental and control group, respectively. Flow cytometry and ELISA were u
Autor:
Y Wang, Yanying Liu, Zhanyun Da, Ling Wang, Fuai Lu, Hua Wei, Xiaowei Gong, Jian Wu, Zhenyu Jiang, Li Luo, Niansheng Yang, Lie Dai, Shengyun Liu, Yingxue Cathy Liu, Kexia Chai, Linjie Chen, Ju Liu, Lijun Wu, Xiumei Liu, Qian Guo, H. Sun, Guixiu Shi, Zhenchun Zhang, Xiaomei Li, Cheng Zhao, Ning Tie, Lingyun Sun, Jinying Lin, Zhanguo Li, Lin Liu, Hui Song
Background: This double-blind, active-controlled, randomized, multicenter phase III study evaluated the efficacy, safety and immunogenicity of GB242, an infliximab biosimilar, vs infliximab (Remicade®) reference product in patients with moderate to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3863bba85fd20d35223cefa0a955406
https://doi.org/10.21203/rs.3.rs-436813/v1
https://doi.org/10.21203/rs.3.rs-436813/v1
Autor:
Li Luo, Ning Tie, H. Sun, Zhenchun Zhang, Zhenyu Jiang, Guixiu Shi, Lie Dai, Yingxue Cathy Liu, Niansheng Yang, Zhanguo Li, Lin Liu, Cheng Zhao, Hui Song, Shengyun Liu, Ju Liu, Xiaowei Gong, Fuai Lu, Xiumei Liu, Kexia Chai, Jinying Lin, Lijun Wu, Linjie Chen, Y Wang, Zhanyun Da, Ling Wang, Hua Wei, Jian Wu, Qian Guo, Yanying Liu, Lingyun Sun, Xiaomei Li
Publikováno v:
SSRN Electronic Journal.
Objectives: This double-blind, active-controlled, randomized, multicenter phase III study evaluated the efficacy, safety and immunogenicity of GB242 , an infliximab biosimilar, vs infliximab (Remicade®) reference product in patients with moderate to
Autor:
Qianzi, Zhan, Guochun, Wang, Xiangyuan, Liu, Jianglin, Zhang, Rong, Mu, Xiaoxia, Zuo, Xiaofeng, Li, Lijun, Wu, Lu, Gong, Hongbin, Li, Xiaofei, Wang, Dongbao, Zhao, Jin, Lin, Shaoxian, Hu, Cheng, Zhao, Feng, Zhan, Bin, Zhou, Yi, Wang, Kexia, Chai, Yi, Gong, Li, Luo, Lie, Dai, Yongfu, Wang
Publikováno v:
Zhonghua yi xue za zhi. 94(1)
To explore the prevalence and characteristics of main organ involvement in adult patients with polymyositis (PM) or dermatomyositis (DM) and determine their specific relative factors.Using unified questionnaire, we retrospectively collected the medic